Merck and the pharmaceutical industry are headline news today. Controversies over public safety, prices, and the ability of the industry to develop the new drugs and vaccines that society needs have been covered worldwide. Roy Vagelos, who was head of research and then CEO at Merck from the mid-1970s through the early 1990s, addresses these issues here. Success with targeted research started Merck on a path that would lead to a series of block-buster therapies that carried the firm to the top of the global industry in the 1990s and Vagelos into the top position at the company. Trained as a physician and scientist, he had to learn how to run a successful business while holding to the highest principles of ethical behavior. He was not always successful. He and his co-author explain where and why he failed to achieve his goals and carefully analyze where he succeeded.
Les mer
1. The puzzle; 2. Professional path; 3. Turn around; 4. New drugs and public safety; 5. Corporate grooming; 6. Winning in global competition; 7. Prices and public interest; 8. Moral leadership; 9. Afterwards.
Les mer
Roy Vagelos, Merck's former CEO, addresses controversial issues that turned the pharmaceutical industry into headlines.

Produktdetaljer

ISBN
9780521683838
Publisert
2006-04-03
Utgiver
Vendor
Cambridge University Press
Vekt
260 gr
Høyde
226 mm
Bredde
150 mm
Dybde
13 mm
Aldersnivå
U, G, P, 05, 01, 06
Språk
Product language
Engelsk
Format
Product format
Heftet
Antall sider
196

Biographical note

P. Roy Vagelos is retired Chairman of Merck and Co., Inc.; Chairman of Regeneron Pharmaceuticals Inc.; and Chairman of Theravance Corporation. Louis Galambos is Professor of History at The Johns Hopkins University in Baltimore, Maryland and the editor of The Papers of Dwight David Eisenhower. He is the coauthor of Networks of Innovation (Cambridge, 1995) and Anytime, Anywhere (Cambridge, 2002).